zoledronic acid has been researched along with Day Blindness in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arkfeld, DG; Ibrahim, M; Metyas, S; Solyman, J; Yeter, KC | 1 |
| Bursztyn, LL; Masri, M; Sheidow, TG | 1 |
| Bedrossian, EH; Peterson, JD | 1 |
1 review(s) available for zoledronic acid and Day Blindness
| Article | Year |
|---|---|
Bisphosphonate-associated orbital inflammation--a case report and review.
Topics: Bone Density Conservation Agents; Diphosphonates; Edema; Eye Pain; Eyelid Diseases; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Orbital Pseudotumor; Osteoporosis, Postmenopausal; Tomography, X-Ray Computed; Uveitis, Anterior; Vision Disorders; Zoledronic Acid | 2012 |
2 other study(ies) available for zoledronic acid and Day Blindness
| Article | Year |
|---|---|
Giant cell arteritis with visual loss following zoledronic acid infusion.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Giant Cell Arteritis; Glucocorticoids; Humans; Imidazoles; Infusions, Parenteral; Osteoporosis; Treatment Outcome; Vision Disorders; Vision, Ocular; Zoledronic Acid | 2014 |
Severe visual loss secondary to retinal toxicity after intravenous use of bisphosphonate in an eye with known chloroquine maculopathy.
Topics: Antirheumatic Agents; Bone Density Conservation Agents; Chloroquine; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Retinal Diseases; Vision Disorders; Zoledronic Acid | 2014 |